NeoGenomics, Inc. (NASDAQ:NEO) has announced plans to present nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. The presentations will showcase data on the company's advanced RaDaR liquid biopsy test, designed for detecting minimal residual disease (MRD). Dr. Shashikant Kulkarni, Chief Scientific Officer, highlighted the performance comparisons of RaDaR against other MRD tests, emphasizing the firm's commitment to innovation in cancer monitoring. Each abstract covers various aspects of cancer testing, including new methodologies and technological advancements in the field. RaDaR has received FDA Breakthrough Device Designation and is validated for use across multiple cancer types, enhancing NeoGenomics' service portfolio for oncologists and pharmaceutical partners.

NeoGenomics, Inc. (NASDAQ:NEO) will host an Investor Day on April 4, 2023, starting at 8:00 am ET, featuring presentations and a Q&A session with its executive team. Pre-registration is available here. The live event will be webcasted on the investor relations page at ir.neogenomics.com, with a replay accessible for 30 days post-event. Based in Fort Myers, FL, NeoGenomics specializes in oncology testing and services, aiming to facilitate cancer diagnosis and treatment through advanced genetics testing and data protection compliance.

NeoGenomics, Inc. (NASDAQ: NEO) has announced a partnership with Massive Bio, an AI-enabled oncology startup, to enhance cancer therapy development. This collaboration aims to streamline the identification of patients eligible for clinical trials through real-time biomarker assessments. NeoGenomics will collaborate with healthcare professionals to facilitate patient consent and screening. The partnership combines NeoGenomics' expertise in cancer diagnostics with Massive Bio's AI-driven concierge services, promising improved patient outcomes and cost efficiencies in precision medicine.

NeoGenomics, Inc. (NASDAQ:NEO) announced the commercial launch of the RaDaR® assay, a liquid biopsy test for minimal residual disease (MRD), which detects trace amounts of circulating tumor DNA post-cancer treatment. Recent studies highlight its effectiveness, especially in breast cancer, and it has been validated for use across multiple cancer types, including colorectal and lung cancers. This personalized test, with a detection limit of 0.001%, has received Breakthrough Device Designation from the FDA. The RaDaR assay aims to enhance treatment decisions by identifying residual disease much earlier than traditional methods.

NeoGenomics, Inc. (NASDAQ: NEO) announced the launch of new genomic tests, including Neo Comprehensive - Solid Tumor and Neo Comprehensive - Myeloid Disorders. These tests enhance their next-generation sequencing (NGS) portfolio, aiming to improve patient care through comprehensive genomic profiling.

The Solid Tumor test analyzes 517 genes, while the Myeloid test focuses on 164 genes related to myeloid neoplasms. Improvements include faster turnaround times and streamlined reporting. Additionally, software tools NeoAccess™ and NeoSeek™ support clinicians in decision-making and patient management.

NeoGenomics, Inc. (NASDAQ: NEO) will participate in a fireside chat at the 44th Annual Raymond James Institutional Investors Conference on March 6, 2023, at 7:30 AM ET. CEO Chris Smith and CFO Jeff Sherman will represent the company. A live audio webcast can be accessed on the Investor Relations section of their website. NeoGenomics specializes in cancer genetics testing and aims to connect patients with therapies. The company operates accredited laboratories across the U.S. and in Switzerland and Singapore, serving various healthcare stakeholders. For more information, updates are available in their SEC filings.

NeoGenomics, a leader in oncology testing, reported a 10% increase in Q4 2022 revenue to $139 million, and a 5% increase in full-year revenue to $510 million. Clinical Services revenue grew by 4% to $108 million, while Pharma Services revenue surged by 41% to $31 million. Despite operational improvements, the net loss for Q4 2022 narrowed to $23 million from $42 million in Q4 2021. The company anticipates FY 2023 consolidated revenue between $545 million and $555 million, projecting a 7% to 9% growth. However, the full-year 2022 net loss expanded to $144 million, emphasizing ongoing challenges despite revenue growth.

NeoGenomics, Inc. (NASDAQ:NEO) has released new findings on the RaDaR® assay, highlighting its ability to detect circulating tumor DNA (ctDNA) in blood, which correlates with responses to neoadjuvant immune therapies in muscle-invasive bladder cancer. Published in Nature Medicine, the study suggests that the absence of ctDNA can indicate effective treatment and potentially allow patients to avoid radical cystectomy. In the Phase 1b/2a NABUCCO trial, 43% of patients in one cohort achieved a complete pathological response, showcasing the assay's clinical utility for personalized cancer care.

NeoGenomics, Inc. (NASDAQ:NEO) announced its plans to release fourth quarter and full year 2022 financial results on February 23, 2023. A webcast and conference call will follow at 8:30 AM EDT that day, where executives will discuss the results. Participants can access the call at (888) 506-0062 (domestic) or (973) 528-0011 (international), with a conference ID of 647216. A replay will be available until March 9, 2023. NeoGenomics specializes in oncology testing and contract research services, catering to healthcare professionals and pharmaceutical clients.